Levocloperastine Fendizoate- a Better, More Effective Antitussive AgentFitness Equipment
A lot of antitussive agents today act centrally and causes central adverse events such as sedation, vomiting, and nausea. Because of this, there has been a search for a peripherally-acting antitussive agent expected to not produce these central adverse effects. However, the peripherally-acting antitussive agents we have today, like levodropropizine, works only in patients whose cough is associated with conditions like bronchitis and asthma. Most of them are not effective in controlling cough related to other diseases.
These limitations have again, led to the search for another antitussive agent, which is levocloperastine fendizoate.
What is levocloperastine fendizoate and how does it work?
Levocloperastine is the levorotatory isomer of DLcloperastine. Fendizoate is a commonly-used compound for the synthesis of antitussive agents. When combined, levocloperastine fendozoate is an antitussive agent that acts both centrally, on the bulbar cough center, and peripherally, on the cough receptors in the tracheobronchial tree. This dual mechanism of action makes levocloperastine fendizoate effective in the treatment of cough associated with many chronic and acute conditions in patients of all ages.
Clinical studies on the effectivity of levocloperastine fendizoate
Old and new clinical studies on levocloperastine fendizoate are directed towards proving its pharmacological effect and comparing its effectivity over other antitussive agents used in cough medications. Large-scale clinical trials conducted by different researchers back in 1992 found out that this antitussive agent demonstrates effects similar to codeine.
In 2004, another clinical trial was conducted in Italy by Aliprandi et al., which had children and adults as study participants. Majority of children who participated have acute bronchial inflammatory conditions, while adult subjects have chronic pulmonary disorders. The effects were observed as early as the first day of treatment, manifested by improvements in subjective, objective, and laboratory parameters. Objective measurements used in the study include reduction in cough frequency and intensity, nighttime disturbances, and difficulties in expectoration. Laboratory measurements include improvements on cardiovascular and respiratory parameters.
This study also compared the effectivity of levocloperastine fendizoate over other antitussive agents such as DLcloperastine, codeine, and levodropropizine. It is found out that levocloperastine fendizoate has faster onset of action and produced substantial reduction in the intensity and frequency of cough. It is also generally well-tolerated by the body, as it does not produce adverse effects such as sedation, dry mouth, and nausea, like other agents do. And unlike codeine, it doesn’t cause addiction or dependence disorders and doesn’t interfere with normal cardiovascular and gastrointestinal functions.
Another important property of levocloperastine fendizoate is its lack of ability to interact with other drugs, which makes it advisable for patients taking medications for other conditions.
Levocloperastine fendizoate is a more effective, yet safer, alternative to many antitussive agents used today. It is currently available now for distribution by many pharmaceutical companies.